Mesenchymal Stem Cell-Secreted Exosomes and Soluble Signals Regulate Breast Cancer Metastatic Dormancy: Current Progress and Future Outlook

Author:

Dai Bei123ORCID,Clark Amanda M.1245,Wells Alan124ORCID

Affiliation:

1. Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA

2. R&D Service, Pittsburgh VA Health System, Pittsburgh, PA 15213, USA

3. School of Medicine, Tsinghua University, Beijing 100084, China

4. Cell Biology Program, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA

5. Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA 15213, USA

Abstract

Breast cancer is most common in women, and in most cases there is no evidence of spread and the primary tumor is removed, resulting in a ‘cure’. However, in 10% to 30% of these women, distant metastases recur after years to decades. This is due to breast cancer cells disseminating to distant organs and lying quiescent. This is called metastatic dormancy. Dormant cells are generally resistant to chemotherapy, hormone therapy and immunotherapy as they are non-cycling and receive survival signals from their microenvironment. In this state, they are clinically irrelevant. However, risk factors, including aging and inflammation can awaken dormant cells and cause breast cancer recurrences, which may happen even more than ten years after the primary tumor removal. How these breast cancer cells remain in dormancy is being unraveled. A key element appears to be the mesenchymal stem cells in the bone marrow that have been shown to promote breast cancer metastatic dormancy in recent studies. Indirect co-culture, direct co-culture and exosome extraction were conducted to investigate the modes of signal operation. Multiple signaling molecules act in this process including both protein factors and microRNAs. We integrate these studies to summarize current findings and gaps in the field and suggest future research directions for this field.

Funder

United States Department of Veterans Affairs

METAvivor

Publisher

MDPI AG

Reference71 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

2. Cancer statistics, 2024;Siegel;CA Cancer J. Clin.,2024

3. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

4. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

5. Factors related to survival rates for breast cancer patients;Dong;Int. J. Clin. Exp. Med.,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3